Target therapy of well-differentiated neuroendocrine tumors
Journal Title: OncoReview - Year 2011, Vol 1, Issue 4
Abstract
Neuroendocrine tumors (NETs) are a heterogenous group of malignancies with variable prognosis and response to treatment. Treatments for advanced neuroendocrine tumors were, until recently, rather limited. Surgery and liver directed therapy both have relatively limited impact, and systemic cytotoxic chemotherapy has minimal efficacy. Somatostatin analogs have been used for years to control disease and neuroendocrine symptoms, without cytotoxic intent. Promising results have emerged from studies evaluating radiolabeled somatostatin analogs and inhibitors of the vascular endothelial growth factor and mammalian target of rapamycin pathways.
Authors and Affiliations
Norbert Szaluś, Mirosław Dziuk
Keywords
Related Articles
- EP ID EP53122
- DOI -
- Views 245
- Downloads 0
Steroid-induced diabetes in oncology
Patients with neoplasms belong to the group of higher risk for developing steroid-induced diabetes. The rules of diagnosis of this form of diabetes do not differ from others of its type, but the course and treatment diff...
Perioperative treatment of oesophageal, oesophago-gastric adenocarcinoma: new standards of care and controversies
Oesophageal, gastroesophageal and gastric cancers represent important diagnostic and therapeutic challenge. Even after radical surgical procedure (R0) 5-year survival remains unsatisfactory. It is assumed that perioperat...
The influence of socio-demographic factors on making a decision related to the disease and treatment in women with breast cancer
Introduction. Socio-demographic factors may affect the decision making associated with the disease and the long-term results of treatment.Objective. Exploring the relationship between socio-demographic factors of women t...
Dylematy w leczeniu raka nerki - pazopanib
Postęp w leczeniu systemowym przerzutowego raka nerki związany jest z rejestracją nowych leków. Przyniosło to poprawę wyników leczenia, ale zmusza również do dokonywania wyboru leku. Decyzja ta jest szczególnie istotna w...
Early molecular response as a criterion of optimal response to chronic myeloid leukemia treatment with tyrosine kinase inhibitors
Maximal reduction of leukemic BCR/ABL-positive cells and achievement of persistent deep molecular response with the chance for sustained treatment-free survival in possibly all patients is a current goal of chronic myelo...